Skoulidis and colleagues showed that STK11/LKB1 mutation is associated with less expression of PD-L1 and decreased infiltrative CTL density, resulting in primary resistance to PD-1-based immunotherapies in both human and murine STK11/LKB1-deficient lung adenocarcinoma (72). The gene discussed is CD274; the disease is lung adenocarcinoma.